XOMA Royalty Corporation has filed an amendment to its previous Form 8-K, supplementing information regarding the Legacy Assets of LAVA Therapeutics N.V. following the acquisition agreement announced on November 21, 2025. This amendment provides additional disclosure related to the transaction.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-033771), on February 02, 2026, and is solely responsible for the information contained therein.